Morgan Stanley
ALZN icon

Morgan Stanley’s Alzamend Neuro ALZN Stock Holding History

Morgan Stanley’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,000
Closed -$19.1K – 8418
2026
Q1 		$19.1K Hold
18,000
– – ﹤0.01% 6748
2025
Q4 		$32.8K Buy
+18,000
New +$40.8K ﹤0.01% 6555
2025
Q2 		– Hold
0
– -$3 – 8098
2025
Q1 		– Hold
0
– – – 8050
2024
Q4 		– Hold
0
– – – 7940
2024
Q3 		– Hold
0
– – – 7886
2024
Q2 		– Hold
0
– – – 7770
2024
Q1 		– Hold
0
– – – 7603
2023
Q4 		– Hold
0
– – – 7623
2023
Q3 		– Hold
0
– – – 7432
2023
Q2 		– Sell
-2
Closed -$1.57K – 7434
2023
Q1 		$1.26K Sell
2
-3
-60% -$2.26K ﹤0.01% 7320
2022
Q4 		$3.77K Buy
5
+2
+67% +$2.9K ﹤0.01% 7224
2022
Q3 		$4K Hold
3
– – ﹤0.01% 7286
2022
Q2 		$3K Hold
3
– – ﹤0.01% 7496
2022
Q1 		$5K Buy
+3
New +$5.63K ﹤0.01% 7570
2021
Q4 		– Hold
0
– -$1K – 7964
2021
Q3 		– Hold
0
– – – 7749
2021
Q2 		– Hold
0
– – – 7515

Other funds holding ALZN

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley's ALZN Position: Q2 2026 in Review

Morgan Stanley sold out of Alzamend Neuro (ALZN) in Q2 2026, closing a stake of 18,000 shares — an estimated $19.1K sold.

Morgan Stanley first reported a position in ALZN in Q1 2022 and held it in 7 quarters. The position peaked at $32.8K in Q4 2025. 12 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

  • Morgan Stanley reported no remaining Alzamend Neuro position as of Q2 2026 after selling out during the quarter.
  • Morgan Stanley sold 18,000 Alzamend Neuro shares in Q2 2026, an estimated $19.1K.
  • Morgan Stanley first reported a position in Alzamend Neuro in Q1 2022 and held it in 7 quarters.
  • Morgan Stanley's Alzamend Neuro position peaked at $32.8K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.